Phibro Animal Health Corporation announced last week, the financial results for its third quarter ended March 31, 2026, and its updated financial guidance for the year ending June 30, 2026.
Highlights for the three months ended March 31, 2026 (compared to the three months ended March 31, 2025:
- Net sales of $383.5 million, an increase of $35.7 million, or 10%
- Net income of $24.0 million, an increase of $3.1 million, or 15%
- Diluted earnings per share of $0.59, an increase of $0.08, or 16%
With the strong performance in 3rd Quarter and expected strength in sales to continue, Phibro further revised guidance for Q4′ 2026 towards higher end. New Guidance suggests –
- Net sales of $1.46 billion to $1.50 billion
- Adjusted EBITDA of $247 million to $255 million
3rd Quarter Sales of USD 383.5 million includes Sales from Poultry Vaccines of USD 38.6 million, a growth of 16% over same period last year. These vaccines portfolio was acquired by Phibro from ABIC of Israel.
